A 350-patient study finds a palm-sized ECG device spots dangerous heart rhythms that hospital-grade monitors miss entirely.
It starts small. A flutter in the chest on the stairs. A dizzy spell that passes before you’ve even sat down. Most people shrug it off, or mention it to a doctor who sends them home with a monitor strapped to their chest for a day or two, and hope the heart misbehaves on cue.
That’s the problem a new study out of the University of Rochester was built to solve, and the results, published in JACC Advances, suggest the standard approach has been missing far more than anyone realized.
Researchers tracked 350 adults who’d shown up with unexplained palpitations, dizziness or lightheadedness – the kind of symptoms that are maddeningly hard to pin down because they come and go. Each patient wore a conventional ambulatory monitor, either a 24-to-48-hour Holter or an extended patch, while also carrying AliveCor’s KardiaMobile 6L, a handheld six-lead ECG device, for 30 days [1].
The twist: patients only had to use the KardiaMobile 6L when something felt off. No continuous wear, no itchy adhesive patches, no waiting for a rhythm problem to happen to coincide with a monitor that’s already been removed.
The gap between the two approaches was stark. Traditional monitors picked up arrhythmias in 27 patients – 7.7% of the group. The handheld device found them in 52, or nearly 15%. Altogether, 39 arrhythmia episodes, more than one in ten of the total, were caught exclusively by the KardiaMobile 6L and missed entirely by the conventional monitors patients were also wearing.
Where it really pulled ahead
The most telling comparison came against extended patch monitors, the ones people wear continuously for a week or longer, on the assumption that more days on the body means more chances to catch something. Among patients using those patches, the patches themselves found arrhythmias in fewer than one in ten cases. The handheld device, used only when symptoms struck, found them in nearly a quarter.
That’s a hard result to explain away. Continuous monitoring should, in theory, have the edge; it’s recording all the time. However, symptom-triggered recordings appear to line up better with the actual moment something goes wrong, rather than hoping a fixed window of days happens to overlap with it.
Among the arrhythmias the handheld device caught and the standard monitors didn’t, atrial fibrillation topped the list. That matters well beyond the study itself. AFib is one of the clearest, best-documented drivers of stroke risk, and it’s notoriously silent. Many people don’t feel it until a serious event forces the diagnosis. A tool that surfaces it earlier, in a doctor’s office rather than an emergency room, buys people time to do something about it.
Dr Wojciech Zareba of the Clinical Cardiovascular Research Center at the University of Rochester, who led the research, put it plainly.
“Symptom-triggered ECG recordings obtained over 30 days were superior to standard 24- or 48-hour Holter recordings and to prolonged multiday recordings in detecting clinically significant arrhythmias. KM6L might be considered as the first line of diagnostic process in individuals with uncertain causes of cardiac symptoms,” he said.
Meanwhile, Dr Dave Albert, AliveCor’s chief medical officer and co-founder, framed it as a workflow problem finally getting solved.
“Traditional short-duration monitoring simply misses too many transient events, creating a costly diagnostic blind spot for clinicians. By empowering patients to capture arrhythmias the moment symptoms occur, we can accelerate accurate diagnoses, optimize clinical workflows, and get patients to life-saving treatment faster,” Albert said.
Usability wasn’t an afterthought
None of this works if patients won’t actually use the device. Here, the numbers held up too: 88% of participants – across a wide age range, two-thirds of them women – said the smartphone app was easy to use, and the same share said the device made them feel more confident tracking their own heart rhythm. Recording quality matched or slightly beat traditional Holter monitors on interpretability.
Cardiovascular disease remains the single biggest reason people don’t reach the healthy, active years they’d hoped for, and undetected arrhythmias like AFib are a quiet, fixable piece of that equation. The appeal of a device patients already carry, that catches problems clinic visits and week-long patches routinely miss, is a shift toward catching the small warning signs of cardiovascular decline before they become the kind of event that shortens a healthspan rather than just interrupting it.
Diagnostics that meet people at the moment of the symptom, rather than asking their heart to misbehave on schedule, are exactly the kind of quiet infrastructure that longevity medicine will need more of.
